Chemotherapy of carcinomas of the digestive tract.
Adjuvant chemotherapy trials in gastric and colorectal carcinomas are reviewed and no clear benefit from such treatment could be observed. To improve existing chemotherapy regimens, several pilot studies were performed in 95 gastric cancer and 85 colorectal carcinomas patients. Response rate for gastric carcinomas using the mitomycin C plus adriamycin plus 5-fluorouracil (5-FU) (FAM) regimen was 40% and was not improved by the addition of nitrosoureas. In colorectal carcinomas none of the combinations used gave better results than 5-FU alone. Fourteen patients with esophageal carcinoma were treated with combination CDDP and the response rate was as high as 50%.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013852:Thiotepa / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008937:Mitomycins; D016685:Mitomycin; D008130:Lomustine; D004317:Doxorubicin; D013852:Thiotepa; D002945:Cisplatin; D005472:Fluorouracil